Gene-expression profiles correlate with the efficacy of anti-EGFR therapy and chemotherapy for colorectal cancer. (Q55058836)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25990448%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

title

Gene-expression profiles correlate with the efficacy of anti-EGFR therapy and chemotherapy for colorectal cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25990448%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

1 reference

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25990448%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

S Takahashi

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25990448%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

7

Iwao Sasaki

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25990448%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

author name string

Masahiro Inoue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25990448%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Hiroshi Soeda

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25990448%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Hideki Shimodaira

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25990448%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Mika Watanabe

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25990448%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Shunsuke Kato

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25990448%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Chikashi Ishioka

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25990448%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

publication date

20 May 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25990448%20AND%20SRC:MED&resulttype=core&format=json

International Journal of Clinical Oncology

8 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25990448%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

volume

20

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25990448%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25990448%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

page(s)

1147-1155

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25990448%20AND%20SRC:MED&resulttype=core&format=json

Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy

8 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS10147-015-0841-4

A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-015-0841-4

Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-015-0841-4

Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-015-0841-4

Phase I/II study of sequential therapy with irinotecan and S-1 for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-015-0841-4

The epidermal growth factor receptor pathway: a model for targeted therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-015-0841-4

Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-015-0841-4

Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-015-0841-4

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-015-0841-4

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-015-0841-4

Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-015-0841-4

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-015-0841-4

Gene Expression Signature to Improve Prognosis Prediction of Stage II and III Colorectal Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-015-0841-4

Gene expression profiling predicts clinical outcome of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-015-0841-4

Poor-prognosis colon cancer is defined by a molecularly distinct subtype and develops from serrated precursor lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-015-0841-4

Clinical usefulness of KRAS, BRAF, and PIK3CA mutations as predictive markers of cetuximab efficacy in irinotecan- and oxaliplatin-refractory Japanese patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-015-0841-4

Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-015-0841-4

PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-015-0841-4

Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-015-0841-4

Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab

21 January 2018

1 reference

12 December 2020

Microsatellite instability in sporadic colon cancer is associated with an improved prognosis at the population level.

1 reference

12 December 2020

1 reference

12 December 2020

Mutation analysis of p53, K-ras, and BRAF genes in colorectal cancer progression

1 reference

12 December 2020

Prediction of breast cancer prognosis by gene expression profile of TP53 status

1 reference

12 December 2020